Safety study of ET-743 in patients with translocation-related sarcomas
Phase 2
- Conditions
- Patients with malignant soft tissue sarcomas of histological types that have been reported to carry chromosomal translocations
- Registration Number
- JPRN-jRCT2080221811
- Lead Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- 37
Inclusion Criteria
Assignment to the best supportive care (BSC) group of the comparative study
- Other
Exclusion Criteria
- Severe concurrent disease
- Other
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Safety<br>CTCAE ver.4.03
- Secondary Outcome Measures
Name Time Method Overall response rate, Disease control rate, Progression free survival, Overall survival<br>RECIST ver.1.1